Vigonvita Life Sciences Co., Ltd. Class H 2630
HKEX · Hong Kong SAR China · Health Technology
HKD 81.20+2.20 (+2.78%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
These ratios divide the lines in the statements below by the current price; both inputs of every value are visible on this page. The P/E on the overview comes from the same calculation. P/E and P/S are left blank for loss-making companies or where revenue is not reported. Not investment advice.
| FY2025 | |
|---|---|
| Revenue | HKD 113.74M |
| Revenue growth (YoY) | — |
| Cost of Revenue | MakklerPRO |
| Gross Profit | MakklerPRO |
| Gross margin | MakklerPRO |
| Operating expenses | MakklerPRO |
| Operating Income | MakklerPRO |
| Operating margin | MakklerPRO |
| EBITDA | MakklerPRO |
| Pre-tax income | MakklerPRO |
| Income tax | MakklerPRO |
| Net Income | -HKD 396.27M |
| Net margin | MakklerPRO |
| Diluted EPS | MakklerPRO |
| Diluted shares | MakklerPRO |
| FY2025 | |
|---|---|
| Cash & equivalents | MakklerPRO |
| Total Current Assets | MakklerPRO |
| Total Assets | HKD 1.44B |
| Total Current Liabilities | MakklerPRO |
| Total Liabilities | MakklerPRO |
| Total debt | MakklerPRO |
| Total Equity | MakklerPRO |
| FY2025 | |
|---|---|
| Cash from Operations | -HKD 107.69M |
| Capital expenditure | MakklerPRO |
| Free cash flow | MakklerPRO |
| Cash from Investing | MakklerPRO |
| Cash from Financing | MakklerPRO |
Standardised statements compiled from the company's annual and interim reports. The "LTM" column covers the last four reported quarters; balance-sheet lines in it are from the latest quarter. Lines the company does not report are left blank rather than approximated. Not investment advice. The company reports in CNY; every figure is converted to HKD at the exchange rate of its own period end (the latest rate for LTM), so it can be compared with the share price.